Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeting apolipoprotein E for treating Alzheimer's disease.

Kelly R Bales1, Steven M Paul2

  • 1Neuroscience Discovery, Roche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.

Neuroscience Letters
|July 24, 2019
PubMed
Summary

The apolipoprotein E ε4 allele is a key risk factor for Alzheimer's disease. This review explores apolipoprotein E's role in disease pathogenesis and potential drug development targets.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Study Protocol to Characterize Symptom Experience During Immune Checkpoint Inhibitor Therapy for Cutaneous Melanoma.

Nursing research·2026
Same author

The phytosterol 24(S)-saringosterol alters lipid homeostasis and inflammatory pathways in a cell-specific manner.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Large fiber contribution to symptoms in chemotherapy-induced peripheral neuropathy in cancer survivors.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same author

An oral allopregnanolone prodrug bypasses liver metabolism via lymphatic transport enabling bioavailability in animals and humans.

Science translational medicine·2026
Same author

Joint nausea and fatigue profiles during chemotherapy identify patients with a higher symptom burden.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same author

Symptom Clusters and Symptom Burden in Cancer Survivors.

Cancer medicine·2026

Area of Science:

  • Neuroscience
  • Genetics
  • Pharmacology

Background:

  • The apolipoprotein E (APOE) ε4 allele is the strongest genetic risk factor for late-onset Alzheimer's disease (AD).
  • Despite a well-established association for over 25 years, targeted therapeutics for APOE in the brain remain limited.
  • Understanding APOE's complex biology is crucial for developing effective AD interventions.

Purpose of the Study:

  • To review current knowledge of apolipoprotein E biology in the brain.
  • To elucidate the relationship between apolipoprotein E and Alzheimer's disease pathogenesis.
  • To identify potential future therapeutic targets within the apolipoprotein E pathway for drug development.

Main Methods:

  • Literature review and synthesis of existing research on apolipoprotein E.
Keywords:
Alzheimer's diseaseApolipoprotein EBeta-amyloidNeurodegenerationTau

Related Experiment Videos

  • Analysis of the role of APOE in Alzheimer's disease mechanisms.
  • Exploration of potential drug development strategies targeting APOE.

    • Main Results:

    • Apolipoprotein E plays a multifaceted role in brain homeostasis and AD pathology.
    • Specific isoforms of APOE differentially impact disease risk and progression.
    • The APOE pathway presents numerous opportunities for novel therapeutic interventions.

    Conclusions:

    • Targeting apolipoprotein E in the brain offers a promising avenue for Alzheimer's disease drug development.
    • Further research into APOE's biological functions is warranted to optimize therapeutic strategies.
    • Developing specific interventions for the APOE pathway could significantly impact Alzheimer's disease treatment.